AlloSite Tx
  • Home
  • About Us
    • Our Mission
    • Our Team
  • Science
    • Pipeline
    • Platform
    • Publications
  • News
  • Contact Us
Select Page

Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease

by 149bio | Oct 10, 2022 | Press Release

Podocytes are lost in urine in many kidney diseases and its integrin receptor α3β1 keeps them in place The company has identified novel allosteric agonist antibodies against α3β1 to anchor podocytes Integrin α3β1 specific agonist antibodies expected to move to...

Recent Posts

  • Allosite Therapeutics to Present Four Posters at American Society of Nephrology Kidney Week 2025
  • AlloSite Therapeutics launches
  • Acquisition of clinical stage integrin activator program from Gossamer Bio
  • Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease

Recent Comments

    Archives

    • October 2025
    • August 2023
    • February 2023
    • October 2022

    Categories

    • Announcement
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org